UTHRUNITED THERAPEUTICS Corp

Nasdaq unither.com


$ 288.24 $ 0.47 (0.16 %)    

Friday, 14-Jun-2024 15:59:57 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 288.06
$ 286.48
$ 0.00 x 0
$ 0.00 x 0
$ 285.98 - $ 288.81
$ 208.62 - $ 288.83
406,565
na
14.32B
$ 0.50
$ 13.63
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 08-01-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-21-2018 12-31-2017 10-K
27 10-25-2017 09-30-2017 10-Q
28 07-27-2017 06-30-2017 10-Q
29 04-26-2017 03-31-2017 10-Q
30 02-22-2017 12-31-2016 10-K
31 10-27-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-28-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 10-27-2015 09-30-2015 10-Q
36 07-28-2015 06-30-2015 10-Q
37 04-28-2015 03-31-2015 10-Q
38 02-24-2015 12-31-2014 10-K
39 10-28-2014 09-30-2014 10-Q
40 07-29-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-united-therapeutics-raises-price-target-to-350

Wells Fargo analyst Tiago Fauth maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target fr...

Core News & Articles

The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Dru...

 jp-morgan-maintains-overweight-on-united-therapeutics-raises-price-target-to-300

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from...

 goldman-sachs-maintains-neutral-on-united-therapeutics-raises-price-target-to-240

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and raises the price target...

 oppenheimer-maintains-outperform-on-united-therapeutics-raises-price-target-to-400

Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target f...

 hc-wainwright--co-reiterates-buy-on-united-therapeutics-maintains-300-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price...

 lung-disease-focused-united-therapeutics-says-it-is-a-compelling-investment-opportunity

United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyv...

 united-therapeutics-q1-2024-gaap-eps-617-beats-556-estimate-sales-677700m-beat-623966m-estimate

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $...

 united-therapeutics-announces-xenothymokidney-transplant

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transp...

 united-therapeutics-announces-1b-accelerated-share-repurchase-program

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has a...

Core News & Articles

Liquidia’s investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hyperte...

 wedbush-reiterates-outperform-on-united-therapeutics-maintains-308-price-target

Wedbush analyst Liana Moussatos reiterates United Therapeutics (NASDAQ:UTHR) with a Outperform and maintains $308 price target.